Ivan Grishagin
Impact in
- Biophysics top 10%
Papers in
-
- Protein Degradation and Inhibitors 2
- Single-cell and spatial transcriptomics 2
- Bioinformatics and Genomic Networks 2
- Co-authors
- Bogdan Olenyuk (2 shared papers)Vladimir E. Nebolsin (2 shared papers)Fedor N. Novikov (2 shared papers)Noel Southall (3 shared papers)Ðắc-Trung Nguyễn (3 shared papers)Maria V. Panova (2 shared papers)Е. Д. Баздырев (2 shared papers)Polina Rusina (1 shared paper)
- Journals
- Proceedings of the National Academy of Sciences (2 papers)Pharmaceuticals (2 papers)Journal of Clinical Oncology (1 paper)Analytical Biochemistry (1 paper)Cancers (1 paper)
- Partner nations
- United StatesUnited KingdomRussia
In The Last Decade
Ivan Grishagin
16 papers receiving 830 citations
Peers
Comparison fields: 5 of 124
- Biophysics 38
- Health Informatics 7
- Cancer Research 66
- Molecular Biology 319
- Neurology 64
Countries citing papers authored by Ivan Grishagin
This map shows the geographic impact of Ivan Grishagin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Grishagin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Grishagin more than expected).
Fields of papers citing papers by Ivan Grishagin
This network shows the impact of papers produced by Ivan Grishagin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Grishagin. The network helps show where Ivan Grishagin may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Grishagin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2014 | 183 | |
| 2 | 2019 | 182 | |
| 3 | 2021 | 120 | |
| 4 | 2014 | 90 | |
| 5 | 2014 | 90 | |
| 6 | 2024 | 54 | |
| 7 | 2021 | 38 | |
| 8 | 2020 | 29 | |
| 9 | 2016 | 14 | |
| 10 | 2022 | 12 | |
| 11 | 2022 | 11 | |
| 12 | 2022 | 4 | |
| 13 | 2022 | 4 | |
| 14 | 2017 | 3 | |
| 15 | 2019 | 3 | |
| 16 | Mebendazole: A candidate FDA approved drug for repurposing in leukaemia | 2016 | 2 |
About Ivan Grishagin
Ivan Grishagin is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Computational Theory and Mathematics, Cancer Research and Infectious Diseases, having authored 16 papers that have together received 839 indexed citations. Recurring topics across this work include Computational Drug Discovery Methods (4 papers), Cancer Genomics and Diagnostics (2 papers), Protein Degradation and Inhibitors (2 papers), Single-cell and spatial transcriptomics (2 papers), Biosimilars and Bioanalytical Methods (2 papers), Bioinformatics and Genomic Networks (2 papers), COVID-19 Clinical Research Studies (2 papers) and Long-Term Effects of COVID-19 (2 papers). The work is most often cited by research in Biophysics (38 citations), Health Informatics (7 citations), Cancer Research (66 citations), Molecular Biology (319 citations) and Neurology (64 citations). Ivan Grishagin has collaborated with scholars based in United States, United Kingdom and Russia. Frequent co-authors include Bogdan Olenyuk, Vladimir E. Nebolsin, Fedor N. Novikov, Noel Southall, Ðắc-Trung Nguyễn, Maria V. Panova, Е. Д. Баздырев, Polina Rusina, Ajit Jadhav and Paramjit S. Arora. Their work appears in journals such as Proceedings of the National Academy of Sciences, Pharmaceuticals, Journal of Clinical Oncology, Analytical Biochemistry and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.